Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – has announced that the US Food and Drug Administration (FDA) has issued a ...

One of the pioneers of in vivo cell therapy, Umoja Biopharma, has cleared another regulatory milestone after getting a fast-track designation from the FDA for its lead candidate for blood cancers, ...

AI company Anthropic and the Gates Foundation have said they will provide $200 million in funding for a programme to support the development of AI for "health, life sciences, education, and economic ...

Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...

Bladder cancer has been billed by AstraZeneca as a key growth area for its immunotherapy Imfinzi, an ambition that has now ...

The Supreme Court of the US has ruled that the abortion pill mifepristone can continue to be prescribed remotely and ...

Biogen has decided to advance its tau-targeting Alzheimer's disease drug diranersen (BIIB080) into a phase 3 trial programme, ...

UK reimbursement authority NICE has recommended that the NHS in England can use AstraZeneca's Imfinzi as the first ...

Khalil Asmar, VP of cardiometabolic health at Lilly UK & Ireland (l), and former England spin bowler Ashley Giles (r). Like ...

Cardiac rhythm management is undergoing a significant shift. For decades, cardiac resynchronisation therapy has helped restore synchrony in patients with heart failure and electrical conduction ...

Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a ...

It’s safe to say that AI has firmly captured the interest of decision-makers across the industry. But, as the space continues ...